ATE375166T1 - Zusammensetzungen und verfahren zur behandlung von diabetes - Google Patents
Zusammensetzungen und verfahren zur behandlung von diabetesInfo
- Publication number
- ATE375166T1 ATE375166T1 AT03757483T AT03757483T ATE375166T1 AT E375166 T1 ATE375166 T1 AT E375166T1 AT 03757483 T AT03757483 T AT 03757483T AT 03757483 T AT03757483 T AT 03757483T AT E375166 T1 ATE375166 T1 AT E375166T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- methods
- treating diabetes
- gastrin
- treating
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 2
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 abstract 1
- 102000004859 Cholecystokinin Receptors Human genes 0.000 abstract 1
- 108090001085 Cholecystokinin Receptors Proteins 0.000 abstract 1
- 102100021022 Gastrin Human genes 0.000 abstract 1
- 102000052874 Gastrin receptors Human genes 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- 230000008629 immune suppression Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000009707 neogenesis Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38703202P | 2002-06-07 | 2002-06-07 | |
| US43059002P | 2002-12-03 | 2002-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375166T1 true ATE375166T1 (de) | 2007-10-15 |
Family
ID=29739925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03757483T ATE375166T1 (de) | 2002-06-07 | 2003-06-09 | Zusammensetzungen und verfahren zur behandlung von diabetes |
| AT07010865T ATE445407T1 (de) | 2002-06-07 | 2003-06-09 | Methoden und kompositionen um diabetes zu behandeln |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07010865T ATE445407T1 (de) | 2002-06-07 | 2003-06-09 | Methoden und kompositionen um diabetes zu behandeln |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20040023885A1 (de) |
| EP (1) | EP1511509B1 (de) |
| JP (1) | JP2005533775A (de) |
| KR (1) | KR20050048542A (de) |
| CN (1) | CN1671407B (de) |
| AT (2) | ATE375166T1 (de) |
| AU (1) | AU2003243501A1 (de) |
| CA (1) | CA2486584A1 (de) |
| DE (2) | DE60329724D1 (de) |
| ES (1) | ES2334268T3 (de) |
| IL (2) | IL165285A0 (de) |
| WO (1) | WO2003103701A1 (de) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| CN1486204A (zh) | 2001-01-12 | 2004-03-31 | ������˹ҩƷ��˾ | 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物 |
| US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| CA2494134A1 (en) * | 2002-05-24 | 2003-12-04 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| ATE375166T1 (de) | 2002-06-07 | 2007-10-15 | Waratah Pharmaceuticals Inc | Zusammensetzungen und verfahren zur behandlung von diabetes |
| EP1837031B1 (de) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methoden und Kompositionen um Diabetes zu behandeln |
| US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| EP1615640B1 (de) * | 2003-04-22 | 2007-01-24 | Wyeth | Antineoplastische zusammensetzungen |
| US20080039379A1 (en) * | 2003-05-27 | 2008-02-14 | Waratah Pharmaceuticals, Inc. | Compositions Comprising Gastrin Compounds and Their Use in Diabetes |
| BRPI0507189A (pt) * | 2004-01-30 | 2007-06-26 | Waratah Pharmaceuticals Inc | uso combinado de um agonista de glp-1 e compostos de gastrina |
| EP1765873A4 (de) * | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | Verfahren und zusammensetzungen unter anwendung von cd3-agonisten |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP1835817B1 (de) * | 2004-12-30 | 2018-02-14 | Hill's Pet Nutrition, Inc. | Zum verzehr durch katzen bestimmte zusammensetzungen |
| AU2006301892A1 (en) * | 2005-10-07 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Combined use of DPP IV inhibitors and gastrin compounds |
| US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
| US11311477B2 (en) * | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
| US7425542B2 (en) * | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| US8226949B2 (en) * | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8084022B2 (en) * | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) * | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US20090326193A1 (en) * | 2006-06-23 | 2009-12-31 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7998927B2 (en) * | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008007933A1 (en) * | 2006-07-14 | 2008-01-17 | Postech Academy-Industry Foundation | Epidermal growth factor increasing insulin secretion and lowering blood glucose |
| ES2586032T3 (es) | 2008-03-28 | 2016-10-11 | Hale Biopharma Ventures, Llc | Administración de composiciones de benzodiazepinas |
| JP2011529078A (ja) * | 2008-07-25 | 2011-12-01 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 自己免疫疾患を治療および予防するための方法および組成物 |
| US8440631B2 (en) | 2008-12-22 | 2013-05-14 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US8940705B2 (en) | 2009-01-09 | 2015-01-27 | The Regents Of The University Of California | Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone |
| CN103796656A (zh) | 2011-06-14 | 2014-05-14 | 哈尔生物药投资有限责任公司 | 苯二氮卓的投与 |
| EP2739277B1 (de) * | 2011-08-03 | 2016-11-23 | Ma, Zhongmin | Behandlung von typ 2-diabetes mit fty720 |
| US8524234B2 (en) | 2011-11-03 | 2013-09-03 | Tolera Therapeutics, Inc | Antibody for selective inhibition of T-cell responses |
| US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| WO2014138003A1 (en) * | 2013-03-04 | 2014-09-12 | Neuralstem, Inc. | Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders |
| WO2017083555A1 (en) | 2015-11-10 | 2017-05-18 | City Of Hope | Conditioning regimens and methods for inducing mixed chimerism |
| US20190000889A1 (en) * | 2015-12-31 | 2019-01-03 | City Of Hope | Methods for treating diabetes |
| WO2019005871A1 (en) * | 2017-06-26 | 2019-01-03 | City Of Hope | METHODS FOR CULTURE OF CELLS OF THE ISLANDS OF LANGERHANS |
| IL280198B2 (en) * | 2018-07-18 | 2026-01-01 | Regenxbio Inc | Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus) |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4376866A4 (de) * | 2021-06-10 | 2025-10-08 | Fouad Kandeel | Zusammensetzungen und verfahren für inselzelltransplantate |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101353A0 (en) | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US5885956A (en) | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
| US6558952B1 (en) | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| JPH09511384A (ja) | 1994-01-24 | 1997-11-18 | リサーチ トライアングル ファーマシューティカルズ リミテッド | 若年型糖尿病の治療 |
| US5624895A (en) * | 1994-02-18 | 1997-04-29 | Georgetown University Medical Center | Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration |
| GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US20040037818A1 (en) | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
| EP1100530B1 (de) | 1998-07-31 | 2003-10-08 | Novo Nordisk A/S | In-vitro stimulation von beta zellen vermehrung |
| US6610535B1 (en) | 2000-02-10 | 2003-08-26 | Es Cell International Pte Ltd. | Progenitor cells and methods and uses related thereto |
| WO2001072290A2 (en) | 2000-03-31 | 2001-10-04 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| CN1486204A (zh) | 2001-01-12 | 2004-03-31 | ������˹ҩƷ��˾ | 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物 |
| EP1412384B1 (de) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
| US7037504B2 (en) | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| CA2494134A1 (en) | 2002-05-24 | 2003-12-04 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| EP1837031B1 (de) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Methoden und Kompositionen um Diabetes zu behandeln |
| ATE375166T1 (de) | 2002-06-07 | 2007-10-15 | Waratah Pharmaceuticals Inc | Zusammensetzungen und verfahren zur behandlung von diabetes |
| JP2006506386A (ja) | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 糖尿病の処置 |
| US20040229810A1 (en) | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| EP1620464A1 (de) | 2003-04-30 | 2006-02-01 | Waratah Pharmaceuticals, Inc. | Kombinierte verwendung von keratinocyte-growth-factor agonisten und gastrin verbindungen |
| RU2005140518A (ru) | 2003-05-27 | 2007-07-10 | Уэйрейта Фармасьютиклз, Инк. (Ca) | Композиции и способы, включающие соединения гастрина |
| BRPI0507189A (pt) | 2004-01-30 | 2007-06-26 | Waratah Pharmaceuticals Inc | uso combinado de um agonista de glp-1 e compostos de gastrina |
| EP1765873A4 (de) | 2004-07-01 | 2009-07-01 | Waratah Pharmaceuticals Inc | Verfahren und zusammensetzungen unter anwendung von cd3-agonisten |
| AU2006301892A1 (en) | 2005-10-07 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Combined use of DPP IV inhibitors and gastrin compounds |
| EP1971363A1 (de) | 2005-12-02 | 2008-09-24 | Waratah Pharmaceuticals, Inc. | Kombinationsbehandlungen mit gastrin-agonisten für diabetes und verwandten erkrankungen |
| WO2007095737A1 (en) | 2006-02-21 | 2007-08-30 | Waratah Pharmaceuticals Inc. | Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound |
-
2003
- 2003-06-09 AT AT03757483T patent/ATE375166T1/de not_active IP Right Cessation
- 2003-06-09 US US10/457,126 patent/US20040023885A1/en not_active Abandoned
- 2003-06-09 WO PCT/US2003/018377 patent/WO2003103701A1/en not_active Ceased
- 2003-06-09 DE DE60329724T patent/DE60329724D1/de not_active Expired - Lifetime
- 2003-06-09 KR KR1020047019788A patent/KR20050048542A/ko not_active Ceased
- 2003-06-09 AU AU2003243501A patent/AU2003243501A1/en not_active Abandoned
- 2003-06-09 EP EP03757483A patent/EP1511509B1/de not_active Expired - Lifetime
- 2003-06-09 US US10/517,135 patent/US7560425B2/en not_active Expired - Fee Related
- 2003-06-09 IL IL16528503A patent/IL165285A0/xx unknown
- 2003-06-09 AT AT07010865T patent/ATE445407T1/de not_active IP Right Cessation
- 2003-06-09 JP JP2004510820A patent/JP2005533775A/ja active Pending
- 2003-06-09 ES ES07010865T patent/ES2334268T3/es not_active Expired - Lifetime
- 2003-06-09 CA CA002486584A patent/CA2486584A1/en not_active Abandoned
- 2003-06-09 CN CN038185261A patent/CN1671407B/zh not_active Expired - Fee Related
- 2003-06-09 DE DE60316798T patent/DE60316798T2/de not_active Expired - Lifetime
-
2004
- 2004-11-18 IL IL165285A patent/IL165285A/en not_active IP Right Cessation
-
2009
- 2009-04-08 US US12/420,212 patent/US20090269337A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1511509A1 (de) | 2005-03-09 |
| IL165285A (en) | 2010-04-29 |
| KR20050048542A (ko) | 2005-05-24 |
| WO2003103701A1 (en) | 2003-12-18 |
| US7560425B2 (en) | 2009-07-14 |
| JP2005533775A (ja) | 2005-11-10 |
| AU2003243501A1 (en) | 2003-12-22 |
| CN1671407B (zh) | 2010-05-26 |
| US20060183674A1 (en) | 2006-08-17 |
| US20040023885A1 (en) | 2004-02-05 |
| ATE445407T1 (de) | 2009-10-15 |
| ES2334268T3 (es) | 2010-03-08 |
| DE60329724D1 (de) | 2009-11-26 |
| DE60316798T2 (de) | 2008-07-24 |
| CA2486584A1 (en) | 2003-12-18 |
| US20090269337A1 (en) | 2009-10-29 |
| EP1511509A4 (de) | 2005-04-27 |
| IL165285A0 (en) | 2005-12-18 |
| CN1671407A (zh) | 2005-09-21 |
| EP1511509B1 (de) | 2007-10-10 |
| DE60316798D1 (de) | 2007-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE375166T1 (de) | Zusammensetzungen und verfahren zur behandlung von diabetes | |
| DE60326002D1 (de) | Behandlung von diabetes. | |
| ATE539701T1 (de) | Zusammengesetzte schlinge zur behandlung von inkontinenz | |
| ATE404574T1 (de) | Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden | |
| NO20013451L (no) | 1-Heterocyklus-substituerte diarylaminer | |
| TR200103756T2 (tr) | Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi. | |
| TW200738270A (en) | Method of treating depression using a TNFα antibody | |
| ZA200701656B (en) | Humanized anti-cment antagonists | |
| DE60321965D1 (de) | Amidfunktionelle polymere, zusammensetzungen und verfahren | |
| TW200600087A (en) | Methods and compositions for treating amyloid-related diseases | |
| MXPA05014166A (es) | Metodos y composiciones para tratar enfermedades relacionadas con amiloide. | |
| CY1112743T1 (el) | Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους | |
| DK1503794T3 (da) | Behandlingsfremgangsmåder ved anvendelse af CTLA-4-antistoffer | |
| TW200621256A (en) | Formulations | |
| IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
| MXPA05010582A (es) | Combinaciones antineoplasicas. | |
| DE60330161D1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| IL213523A0 (en) | Compositions comprising blood group antigens | |
| ATE423990T1 (de) | Verfahren und zusammensetzungen zur behandlung von uveitis | |
| TR199901104T2 (xx) | Farmas�tik bile�ikler. | |
| DE69915310D1 (de) | Methoden zur behandlung der salzabhängigen hypertonie | |
| TW200616639A (en) | Methods for treating a mammal before, during and after cardiac arrest | |
| ES2167678T3 (es) | Tratamiento y profilaxis de la pancreatitis. | |
| NO20060093L (no) | Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav | |
| DK1189627T3 (da) | Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |